DavidRosenberg wrote: Are the value part ultimately clinical trial stuff will be the ultimate thing that brings value
this is an example from life sci advisors
Fantastic news for three LifeSci clients who were acquired this morning:
Amryt Pharma (AMYT) to be bought by Chiesi Farmaceutici (private) in a $1.48B deal. This transaction adds four approved drugs for rare diseases to Chiesi’s portfolio. Terms include $14.50/ADS in cash and CVR worth up to $2.50/ADS linked to Filsuvez. AMYT closed at $7.00 on Friday.
Read the full press release here: https://lnkd.in/ejCzPV6b
Albireo (ALBO) to be bought by Ipsen in up to $1.22B deal. The acquisition adds orphan-designated Bylvay to Ipsen’s rare disease unit. Terms include $952M upfront at $42/share in cash and CVR worth up to $10/share, tied to future successes for Bylvay (odevixibat).
Read the full press release here:
https://lnkd.in/eMuFqVkb
CinCor Pharma (CINC) to be bought by AstraZeneca (AZN.FP) for up to $1.8B in a deal that adds baxdrostat for uncontrolled hypertension to the AZ portfolio. Terms include $26/share in cash and CVR worth up to $10/share tied to the lead candidate.
Read the full press release here:
https://lnkd.in/e3WWHFya